Double-Barreled Biologic for Diabetic Retinopathy Emerging

Source: Medscape

Investigators searching for new ways to manage diabetic macular edema are targeting pathways beyond vascular endothelial growth factor (VEGF), the only pathway for which there are approved therapies, and are developing treatments that can be administered less often, according to a Medscape report.

Phase 2 results from the BOULEVARD trial (NCT02699450), which is comparing faricimab, the first biologic to target both the Ang-2 and VEGF pathways, with ranibizumab, will be presented at the American Society of Retina Specialists (ASRS) 2019 Annual Meeting. The drug, from Roche and Genentech, is currently in phase 3 trials.

Read the full article.

Related Content